uBiome, a San Francisco, CA-based microbial genomics company, raised $22m in Series B funding.
The round was led by 8VC, with participation from Slow Ventures, Stanford’s StartX Fund, and angel investors.
The company, which has now raised $27m in total funding, will use the funds to continue to expand its product offerings.
Founded in 2012 by Dr. Jessica Richman, CEO, and Dr. Zachary Apte, CTO, uBiome is a microbial genomics company which aims to explore important research questions about the microbiome and to develop accurate clinical tests based on the microbiome.
The company has just launched SmartGut™, a sequencing-based clinical microbiome screening test which enables patient and doctor to access to a comprehensive microbiome screening test — with an at-home sample collection – that identifies important commensal and pathogenic microorganisms.
The test uses 16S rRNA gene sequencing and a custom bioinformatics pipeline to identify dozens of microbial genera and species—more than any other test currently on the market—associated with specific infections, health risks, and gut conditions.